Online citations, reference lists, and bibliographies.
← Back to Search

Lipase Degradation Of Dynasan 114 And 116 Solid Lipid Nanoparticles (SLN)--effect Of Surfactants, Storage Time And Crystallinity.

C. Olbrich, O. Kayser, R. Mueller
Published 2002 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
In vivo drug release from solid lipid nanoparticles (SLN) takes place by diffusion and degradation of the lipid matrix. SLN with different degree of crystallinity were prepared to study the effect of crystallinity on the degradation velocity. These SLN were produced by using glycerides with different length of fatty acid chains and known differences in crystallisation velocity (Dynasan 114 and 116), and using stabilisers interfering differently with the crystallisation process of the lipid matrix (cholic acid sodium salt (NaCh), Poloxamer 407 (Plx 407)). NaCh disturbs the crystallisation process, Poloxamer shows little interference. The particles were characterised by photon correlation spectroscopy (PCS) and differential scanning calorimetry (DSC), degradation velocity was determined directly after production and during storage up to 4 weeks under different storage conditions using an especially developed assay based on the NEFA Test kit. After production, SLN with a lower crystallinity matrix (Dynasan 114 and 116, NaCh) degraded faster than higher crystalline particles (all SLN with Plx 407), and showed a decrease in degradation velocity with increasing crystallinity during storage. Fast crystallising particles made from Dynasan 116 stabilised with the non-interfering Plx 407 showed no change in the degradation velocity during storage. SLN produced with a higher crystalline lipid in combination with the crystallisation-disturbing NaCh (Dynasan 116, NaCh) required a 'ripening time' to reach sufficient crystallinity.
This paper references
10.1038/343771A0
Structure of human pancreatic lipase
F. Winkler (1990)
10.1016/0378-5173(95)04286-5
Crystallization tendency and polymorphic transitions in triglyceride nanoparticles
H. Bunjes (1996)
Effects of some experimental factors on the production process of solid lipid nanoparticles
R. Cavalli (1996)
10.1016/S0378-5173(98)00404-9
Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures.
C. Olbrich (1999)
10.1016/0927-7765(94)80063-4
Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles
B. Siekmann (1994)
10.1016/0378-5173(94)00347-8
Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix
K. Westesen (1995)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1023/A:1020159331420
Enzymatic Degradation of Dynasan 114 SLN – Effect of Surfactants and Particle Size
C. Olbrich (2002)
10.1016/S0939-6411(97)00150-1
Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism.
A. Zur Mühlen (1998)
Solid lipid nanoparticles (SLN) : an alternative colloidal carrier system for controlled drug delivery
R. Mueller (1995)
10.1016/S0939-6411(99)00075-2
Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin.
V. Jenning (2000)
10.1016/S0378-5173(96)04782-5
Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate
H. Heiati (1997)



This paper is referenced by
10.3109/03639045.2014.938082
PEGylated nanostructured lipid carriers (PEG–NLC) as a novel drug delivery system for biochanin A
L. Wang (2015)
Lipids in Health and Disease
Kesavan Bhaskar (2009)
10.1080/03639040802192822
Development of SLN and NLC Enriched Hydrogels for Transdermal Delivery of Nitrendipine: In Vitro and In Vivo Characteristics
K. Bhaskar (2009)
10.7243/2050-120X-2-4
Testosterone undecanoate – increase of oral bioavailability by nanostructured lipid carriers (NLC)
M. Muchow (2013)
10.1016/J.ADDR.2007.04.011
Solid lipid nanoparticles for targeted brain drug delivery.
P. Blasi (2007)
Enhanced Blood – Brain Barrier Transmigration Using the Novel Chrysin Embedded Solid Lipid Nanoformulation : A Salient Approach on Physico-Chemical Characterization , Pharmacokinetics and Biodistribution Studies
Sumathi Aishwarya V (2017)
10.3354/dao03129
Treatment of Francisella infections via PLGA- and lipid-based nanoparticle delivery of antibiotics in a zebrafish model.
Lilia S. Ulanova (2017)
10.1007/s40005-013-0101-4
Coenzyme Q10 oral bioavailability: effect of formulation type
A. Barakat (2013)
Évaluation d'une forme galénique à base d'alpha cyclodextrine et d'huile végétale pour l'administration par voie orale de molécules actives peu solubles dans l'eau
M. Hamoudi (2012)
PITC-2 Loaded Solid Lipid Nanoparticle: Design, Preparation, Characterization and Therapeutic Comparison with Free Phytochemical PITC-2 Isolated from Tissue Cultured Plant Pluchea Indica
Soumita Goswami (2019)
10.1111/J.1750-3841.2007.00507.X
Emulsion-based delivery systems for lipophilic bioactive components.
D. J. Mcclements (2007)
10.1016/B978-0-12-801406-6.00006-6
Nanoparticle Pharmacokinetics and Toxicokinetics
Ashutosh Kumar Singh (2016)
10.3109/03639045.2014.972412
In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract
V. Jannin (2015)
UNIVERZA V LJUBLJANI FAKULTETA ZA FARMACIJO URŠKA TREIBER UPORABNOST DIFERENČNE DINAMIČNE KALORIMETRIJE ZA DOLOČANJE KONCENTRACIJE UČINKOVINE V LIPIDNIH NANODELCIH APPLICABILITY OF DIFFERENTIAL SCANNING CALORIMETRY FOR THE DETERMINATION OF DRUG CONCENTRATION IN LIPID NANOPARTICLES
UNIVERZA V LJUBLJANI (2014)
10.1016/J.COLSURFA.2014.04.032
Preparation and characterization of a nanostructured lipid carrier for a poorly soluble drug
Yiyin Chen (2014)
10.1016/J.JCONREL.2004.02.027
Continuous release of rh-interferon α-2a from triglyceride matrices
S. Mohl (2004)
The Development of a Sustained and Controlled Release Device for Pharmaceutical Proteins based on Lipid Implants
S. Mohl (2004)
10.5772/58423
Nanoparticle based Drug Delivery Systems for Treatment of Infectious Diseases
M. Salouti (2014)
10.2174/2211738511301010068
Preparation, Characterization and in vivo Evaluation of Raloxifene Hydrochloride Solid Lipid Nanoparticles
V. Nekkanti (2012)
10.1504/IJBNN.2010.034649
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) enriched hydrogels for transdermal delivery of flurbiprofen: formulation, in vitro characterisation, pharmacokinetic and pharmacodynamic studies in animals
Kesavan Bhaskar (2010)
10.22159/IJPPS.2016V8I10.13207
SOLID LIPID NANOPARTICLE: FABRICATED THROUGH NANOPRECIPITATION AND THEIR PHYSICOCHEMICAL CHARACTERIZATION
A. Sharma (2016)
10.1208/s12249-014-0168-x
Characterization and Evaluation of 5-Fluorouracil-Loaded Solid Lipid Nanoparticles Prepared via a Temperature-Modulated Solidification Technique
M. Patel (2014)
10.1080/10611860600888850
Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration
K. Manjunath (2006)
10.4172/2157-7439.1000412
Targeting Efficacy of Simvastatin for Hormone-Dependent Carcinomasthrough Solid Lipid Nanoparticles
U. Dasam (2016)
10.4155/TDE.10.4
Nanoparticulate strategies for effective delivery of poorly soluble therapeutics.
E. Gokce (2010)
10.2478/v10007-012-0040-z
Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled
C. Pardeshi (2012)
10.1007/s13204-014-0361-y
Formulation of enrofloxacin SLNs and its pharmacokinetics in emu (Dromaius novaehollandiae) birds
P. Senthil Kumar (2014)
10.1002/jps.24044
Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram.
G. Leyva-Gómez (2014)
10.1201/9780203505281.CH3
Characterization of Solid Lipid Nano-and Microparticles
H. Bunjes (2004)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1002/9783527610419.NTLS0257
Solid Lipid Nanoparticles to Improve Brain Drug Delivery
P. Blasi (2012)
10.1208/pt060224
Etoposide-loaded nanoparticles made from glyceride lipids: Formulation, characterization, in vitro drug release, and stability evaluation
L. Harivardhan Reddy (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar